NOP Receptor/ORL1 Antagonist
- 1
-
JTC-801
0 ImagesJTC-801 is a selective opioid receptor-like1 (ORL1) receptor antagonist, binding to ORL1 receptor with a Ki value of 8.2 nM.
-
LY2940094
0 ImagesSynonyms: BTRX-246040LY2940094 (BTRX-246040) is a potent, selective and orally available nociceptin receptor (NOP receptor) antagonist with high affinity (Ki=0.105 nM) and antagonist potency (Kb=0.166 nM). LY2940094 reduces ethanol self-administration in animal models.
-
(±)-J-113397
0 Images(±)-J-113397 is a potent and selective non-peptidyl ORL1 receptor antagonist with a Ki of 1.8 nM for cloned human ORL1. J-113397 inhibited nociceptin/orphanin FQ-stimulated GTPγS binding to CHO cells expressing ORL1 with an IC50 value of 5.3 nM. J-113397 can be used for researching the physiological roles of nociceptin/orphanin FQ.
-
J-113397
0 ImagesJ-113397 is the first potent and selective nonpeptidyl ORL1 receptor antagonist (Ki: cloned human ORL1=1.8 nM) without any agonistic effects on other opioid receptors.
-
AT-076
0 ImagesCat. No.: HY-106732CAS No.: 1657028-64-2AT-076 is an opioid pan antagonist at nociception, kappa, mu, and delta opioid receptors, with Ki values of 1.75 nM (NOP), 1.67 nM (MOP), 1.14 nM (KOP) and 19.6 nM (DOP), respectively.
-
MK-5757
0 ImagesCat. No.: HY-14124CAS No.: 919482-44-3MK-5757 is a Nociceptin/Orphanin FQ Peptide Receptor antagonist. ORL1 antagonist 3 can improve cerebral blood flow disorders and ischemic damage, and alleviate abnormal neurological symptoms. ORL1 antagonist 3can be used for the research of neurological disease, such as traumatic brain injury.
-
NOP antagonist 1
0 ImagesCat. No.: HY-176505CAS No.: 1283095-64-6NOP antagonist 1 (Compound (-)-31) is a nociceptin opioid peptide (NOP) antagonist with a Kb of 8.65 nM. NOP antagonist 1 can be used for neuropsychiatric disorders research.
-
Trap-101 hydrochloride
0 ImagesCat. No.: HY-11052ACAS No.: 1216621-00-9Trap-101 hydrochloride is a potent, selective and competitive antagonist of NOP receptors over classical opioid receptors. Trap-101 stimulates GTPγ35S binding to CHOhNOP membranes with pKi values of 8.65, 6.60, 6.14 and <5 for NOP, μ-, κ-, and δ-opioid receptors, respectively. Trap-101 attenuates motor deficits in a rat model of parkinson's disease and can be used for the research of nervous system diseases.
-
UFP-101
0 ImagesCat. No.: HY-P1299CAS No.: 849024-68-6UFP-101 is a potent, selective, and competitive antagonist of the NOP receptor, with a pKi of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 shows antidepressant-like effect.
- 1
